Haleon (HLN) Non-Current Deferred Tax Liability (2021 - 2026)
Haleon's (HLN) quarterly Non-Current Deferred Tax Liability came in at -$4.4 billion in Q2 2026, down 2.22% on a QoQ basis from -$4.3 billion in Q4 2025.
Haleon (HLN) Non-Current Deferred Tax Liability (2021 - 2026) Analysis & Trends
Haleon (HLN) has 6 years of Non-Current Deferred Tax Liability data on file, last reported at -$4.4 billion in Q2 2026.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to -$4.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$4.4 billion (changed N/A YoY) and the FY2025 annual result came in at -$4.3 billion, down 199.99% from the prior year.
- Non-Current Deferred Tax Liability retreated to -$4.4 billion in Q2 2026, from -$4.3 billion in the prior quarter.
- In the past five years, Non-Current Deferred Tax Liability ranged from a high of $4.3 billion in Q4 2023 to a low of -$4.6 billion in Q2 2022.
- A 5-year average of -$1.1 billion and a median of -$4.3 billion in 2024 frame the typical range for Non-Current Deferred Tax Liability.
- Annual changes were most pronounced in 2023 — Non-Current Deferred Tax Liability rose 6.5% — and 2025, when it sank 200.31%.
- Tracing HLN's Non-Current Deferred Tax Liability over 5 years: stood at $4.2 billion in 2022, then rose by 2.47% to $4.3 billion in 2023, then retreated by 0.56% to $4.3 billion in 2024, then slumped by 200.31% to -$4.3 billion in 2025, then retreated by 2.22% to -$4.4 billion in 2026.
- The last three Non-Current Deferred Tax Liability figures came in at -$4.4 billion (Q2 2026), -$4.3 billion (Q4 2025), and $4.3 billion (Q4 2024), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.76 Bn | 42.79 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.38 Bn | 39.73 Bn | 2.15 Bn |
| 3 | Zoetis | 31.61 Bn | 29.93 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.64 Bn | 22.84 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.54 Bn | 683.80 Mn |
| 6 | Viatris | 18.82 Bn | 17.93 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.67 Bn | 15.28 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 12.11 Bn | 11.58 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | Alkermes | 8.21 Bn | 7.55 Bn | 397.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -4.41 Bn |
| Jun 30, 2026 | -4.41 Bn |
| Dec 31, 2025 | -4.32 Bn |
| Dec 31, 2025 | -4.32 Bn |
| Dec 31, 2024 | 4.30 Bn |
| Dec 31, 2024 | 4.30 Bn |
| Jun 30, 2024 | -4.22 Bn |
| Jun 30, 2024 | -4.22 Bn |
| Dec 31, 2023 | 4.33 Bn |
| Dec 31, 2023 | 4.33 Bn |
| Jun 30, 2023 | -4.30 Bn |
| Jun 30, 2023 | -4.30 Bn |
| Dec 31, 2022 | 4.22 Bn |
| Dec 31, 2022 | 4.22 Bn |
| Jun 30, 2022 | -4.60 Bn |
| Jun 30, 2022 | -4.60 Bn |
| Dec 31, 2021 | 4.53 Bn |
| Dec 31, 2021 | 4.53 Bn |